These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
147 related articles for article (PubMed ID: 8496990)
21. The role of gadolinium-diethylenetriaminepentaacetic acid in the evaluation of the central nervous system. Runge VM; Gelblum DY Magn Reson Q; 1990 Apr; 6(2):85-107. PubMed ID: 2202425 [No Abstract] [Full Text] [Related]
22. MR evaluation of CNS tumors: dose comparison study with gadopentetate dimeglumine and gadoteridol. Yuh WT; Fisher DJ; Engelken JD; Greene GM; Sato Y; Ryals TJ; Crain MR; Ehrhardt JC Radiology; 1991 Aug; 180(2):485-91. PubMed ID: 2068317 [TBL] [Abstract][Full Text] [Related]
23. Multicenter study of gadodiamide injection as a contrast agent in MR imaging of the brain and spine. Sze G; Brant-Zawadzki M; Haughton VM; Maravilla KR; McNamara MT; Kumar AJ; Aisen AM; Dreisbach JN; Bradley WG; Weinreb JC Radiology; 1991 Dec; 181(3):693-9. PubMed ID: 1947084 [TBL] [Abstract][Full Text] [Related]
24. Comparative analysis of ferumoxytol and gadoteridol enhancement using T1- and T2-weighted MRI in neuroimaging. Hamilton BE; Nesbit GM; Dosa E; Gahramanov S; Rooney B; Nesbit EG; Raines J; Neuwelt EA AJR Am J Roentgenol; 2011 Oct; 197(4):981-8. PubMed ID: 21940589 [TBL] [Abstract][Full Text] [Related]
26. Magnetic resonance imaging of an experimental model of intracranial metastatic disease. A study of lesion detectability. Runge VM; Wells JW; Williams NM Invest Radiol; 1994 Dec; 29(12):1050-6. PubMed ID: 7721546 [TBL] [Abstract][Full Text] [Related]
27. Magnetic resonance evaluation of brain metastases from systemic malignances with two doses of gadobutrol 1.0 m compared with gadoteridol: a multicenter, phase ii/iii study in patients with known or suspected brain metastases. Katakami N; Inaba Y; Sugata S; Tsurusaki M; Itoh T; Machida T; Tanaka H; Nakayama T; Morikawa T; Breuer J; Aitoku Y Invest Radiol; 2011 Jul; 46(7):411-8. PubMed ID: 21467949 [TBL] [Abstract][Full Text] [Related]
28. Comparison between two separate injections and a single injection of double-dose contrast medium for contrast-enhanced MR imaging of metastatic brain tumors. Ochi T; Taoka T; Matsuda R; Sakamoto M; Akashi T; Tamamoto T; Sugimoto T; Sakaguchi H; Hasegawa M; Nakase H; Kichikawa K Magn Reson Med Sci; 2014; 13(4):221-9. PubMed ID: 25167875 [TBL] [Abstract][Full Text] [Related]
29. Gadoteridol for MR imaging of lymphatic vessels in lymphoedematous patients: initial experience after intracutaneous injection. Lohrmann C; Foeldi E; Bartholomae JP; Langer M Br J Radiol; 2007 Jul; 80(955):569-73. PubMed ID: 17704317 [TBL] [Abstract][Full Text] [Related]
30. [Clinical evaluation of the tolerability of gadodiamide, a new nonionic contrast agent in MRI of the central nervous system]. Aslanian V; Lemaignen H; Bunouf P; Schiratti M; Lambrechts M; Lundby B; Borseth A; Svaland M J Radiol; 1995 Jul; 76(7):431-4. PubMed ID: 7473377 [TBL] [Abstract][Full Text] [Related]
31. [Enhanced MR imaging with a nonionic contrast gadolinium complex, Gadoteridol, for lumbar disc herniation]. Nakashima A; Nakashima K; Sugawara Y; Kawamura K Nihon Igaku Hoshasen Gakkai Zasshi; 1998 Apr; 58(5):221-5. PubMed ID: 9617157 [TBL] [Abstract][Full Text] [Related]
32. Contrast-enhanced MRI of murine sponge model for progressive angiogenesis assessed with gadoteridol (ProHance) and gadocoletic acid trisodium salt (B22956/1). Ramponi S; Rebaudengo C; Cabella C; Grotti A; Vultaggio S; Aime S; Morisetti A; Lorusso V J Magn Reson Imaging; 2008 Apr; 27(4):872-80. PubMed ID: 18383249 [TBL] [Abstract][Full Text] [Related]
33. Investigation of the ototoxicity of gadoteridol (ProHance) and gadodiamide (Omniscan) in mice. Nonoyama H; Tanigawa T; Shibata R; Tanaka H; Katahira N; Horibe Y; Takemura K; Murotani K; Ozeki N; Ueda H Acta Otolaryngol; 2016 Nov; 136(11):1091-1096. PubMed ID: 27315460 [TBL] [Abstract][Full Text] [Related]
34. Evaluation of the clinical safety of gadodiamide injection, a new nonionic MRI contrast medium for the central nervous system: a European perspective. Aslanian V; Lemaignen H; Bunouf P; Svaland MG; Borseth A; Lundby B Neuroradiology; 1996 Aug; 38(6):537-41. PubMed ID: 8880714 [TBL] [Abstract][Full Text] [Related]
35. Incidence of immediate gadolinium contrast media reactions. Prince MR; Zhang H; Zou Z; Staron RB; Brill PW AJR Am J Roentgenol; 2011 Feb; 196(2):W138-43. PubMed ID: 21257854 [TBL] [Abstract][Full Text] [Related]
36. Update: safety, new applications, new MR agents. Runge VM; Wells JW Top Magn Reson Imaging; 1995; 7(3):181-95. PubMed ID: 7654396 [TBL] [Abstract][Full Text] [Related]
37. MR imaging of the myocardium using nonionic contrast medium: signal-intensity changes in patients with subacute myocardial infarction. Dulce MC; Duerinckx AJ; Hartiala J; Caputo GR; O'Sullivan M; Cheitlin MD; Higgins CB AJR Am J Roentgenol; 1993 May; 160(5):963-70. PubMed ID: 8470611 [TBL] [Abstract][Full Text] [Related]